|
1
|
Baron R: Peripheral neuropathic pain: From
mechanisms to symptoms. Clin J Pain. 16(Suppl 2): S12–S20. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sorge RE, Trang T, Dorfman R, Smith SB,
Beggs S, Ritchie J, Austin JS, Zaykin DV, Vander Meulen H, Costigan
M, et al: Genetically determined P2X7 receptor pore formation
regulates variability in chronic pain sensitivity. Nat Med.
18:595–599. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neville A, Peleg R, Singer Y, Sherf M and
Shvartzman P: Chronic pain: A population-based study. Isr Med Assoc
J. 10:676–680. 2008.PubMed/NCBI
|
|
4
|
O'Connor AB and Dworkin RH: Treatment of
neuropathic pain: An overview of recent guidelines. Am J Med.
122(Suppl 10): S22–S32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
von Schack D, Agostino MJ, Murray BS, Li
Y, Reddy PS, Chen J, Choe SE, Strassle BW, Li C, Bates B, et al:
Dynamic changes in the microRNA expression profile reveal multiple
regulatory mechanisms in the spinal nerve ligation model of
neuropathic pain. PLoS One. 6:e176702011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aldrich BT, Frakes EP, Kasuya J, Hammond
DL and Kitamoto T: Changes in expression of sensory organ-specific
microRNAs in rat dorsal root ganglia in association with mechanical
hypersensitivity induced by spinal nerve ligation. Neuroscience.
164:711–723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakai A and Suzuki H: Emerging roles of
microRNAs in chronic pain. Neurochem Int. 77:58–67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang HL, Wang HC, Chunag YT, Chou CW, Lin
IL, Lai CS, Chang LL and Cheng KI: miRNA expression change in
dorsal root ganglia after peripheral nerve injury. J Mol Neurosci.
61:169–177. 2017. View Article : Google Scholar
|
|
10
|
Li H, Huang Y, Ma C, Yu X, Zhang Z and
Shen L: MiR-203 involves in neuropathic pain development and
represses Rap1a expression in nerve growth factor differentiated
neuronal PC12 cells. Clin J Pain. 31:36–43. 2015. View Article : Google Scholar
|
|
11
|
Tan Y, Yang J, Xiang K, Tan Q and Guo Q:
Suppression of microRNA-155 attenuates neuropathic pain by
regulating SOCS1 signalling pathway. Neurochem Res. 40:550–560.
2015. View Article : Google Scholar
|
|
12
|
Moss A, Beggs S, Vega-Avelaira D, Costigan
M, Hathway GJ, Salter MW and Fitzgerald M: Spinal microglia and
neuropathic pain in young rats. Pain. 128:215–224. 2007. View Article : Google Scholar
|
|
13
|
Miljanich G, Rauck R and Saulino M: Spinal
mechanisms of pain and analgesia. Pain Pract. 13:114–130. 2013.
View Article : Google Scholar
|
|
14
|
Scholz J and Woolf CJ: The neuropathic
pain triad: Neurons, immune cells and glia. Nat Neurosci.
10:1361–1368. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moalem G and Tracey DJ: Immune and
inflammatory mechanisms in neuropathic pain. Brain Res Brain Res
Rev. 51:240–264. 2006. View Article : Google Scholar
|
|
16
|
Shen W, Hu XM, Liu YN, Han Y, Chen LP,
Wang CC and Song C: CXCL12 in astrocytes contributes to bone cancer
pain through CXCR4-mediated neuronal sensitization and glial
activation in rat spinal cord. J Neuroinflammation. 11:752014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu B, Wang C, Wang M, Li W, Chen F, Tracey
KJ and Wang H: Molecular mechanism and therapeutic modulation of
high mobility group box 1 release and action: An updated review.
Expert Rev Clin Immunol. 10:713–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andersson U and Tracey KJ: HMGB1 in
sepsis. Scand J Infect Dis. 35:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li ZC, Cheng GQ, Hu KZ, Li MQ, Zang WP,
Dong YQ, Wang WL and Liu ZD: Correlation of synovial fluid HMGB-1
levels with radiographic severity of knee osteoarthritis. Clin
Invest Med. 34:E2982011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mantell LL, Parrish WR and Ulloa L: Hmgb-1
as a therapeutic target for infectious and inflammatory disorders.
Shock. 25:4–11. 2006. View Article : Google Scholar
|
|
21
|
Basta G: Receptor for advanced glycation
endproducts and atherosclerosis: From basic mechanisms to clinical
implications. Atherosclerosis. 196:9–21. 2008. View Article : Google Scholar
|
|
22
|
den Dekker WK, Cheng C, Pasterkamp G and
Duckers HJ: Toll-like receptor 4 in atherosclerosis and plaque
destabilization. Atherosclerosis. 209:314–320. 2010. View Article : Google Scholar
|
|
23
|
Friggeri A, Yang Y, Banerjee S, Park YJ,
Liu G and Abraham E: HMGB1 inhibits macrophage activity in
efferocytosis through binding to the alphavbeta3-integrin. Am J
Physiol Cell Physiol. 299:C1267–C1276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Andersson U, Erlandsson-Harris H, Yang H
and Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol.
72:1084–1091. 2002.PubMed/NCBI
|
|
25
|
Chacur M, Milligan ED, Gazda LS, Armstrong
C, Wang H, Tracey KJ, Maier SF and Watkins LR: A new model of
sciatic inflammatory neuritis (SIN): Induction of unilateral and
bilateral mechanical allodynia following acute unilateral
peri-sciatic immune activation in rats. Pain. 94:231–244. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shibasaki M, Sasaki M, Miura M, Mizukoshi
K, Ueno H, Hashimoto S, Tanaka Y and Amaya F: Induction of high
mobility group box-1 in dorsal root ganglion contributes to pain
hypersensitivity after peripheral nerve injury. Pain. 149:514–521.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Otoshi K, Kikuchi S, Kato K, Sekiguchi M
and Konno S: Anti-HMGB1 neutralization antibody improves
pain-related behavior induced by application of autologous nucleus
pulposus onto nerve roots in rats. Spine. 36:E692–E698. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maeda T, Ozaki M, Kobayashi Y, Kiguchi N
and Kishioka S: HMGB1 as a potential therapeutic target for
neuropathic pain. J Pharmacol Sci. 123:301–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wan W, Cao L, Khanabdali R, Kalionis B,
Tai X and Xia S: The emerging role of HMGB1 in neuropathic pain: A
potential therapeutic target for neuroinflammation. J Immunol Res.
2016:64304232016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu G, Zhang Z, Wei J, Zhang Y, Zhang Y,
Guo L and Liu X: microR-142-3p down-regulates IRAK-1 in response to
Mycobacterium bovis BCG infection in macrophages. Tuberculosis
(Edinb). 93:606–611. 2013. View Article : Google Scholar
|
|
31
|
Naqvi AR, Fordham JB and Nares S: miR-24,
miR-30b, and miR-142-3p regulate phagocytosis in myeloid
inflammatory cells. J Immunol. 194:1916–1927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Guo Y, Wang C and Yu H, Yu X and
Yu H: MicroRNA-142-3p Inhibits chondrocyte apoptosis and
inflammation in osteoarthritis by targeting HMGB1. Inflammation.
39:1718–1728. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang ZJ, Li HC, Cowan AA, Liu S, Zhang YK
and Song XJ: Chronic compression or acute dissociation of dorsal
root ganglion induces cAMP-dependent neuronal hyperexcitability
through activation of PAR2. Pain. 153:1426–1437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
35
|
Norcini M, Sideris A, Martin Hernandez LA,
Zhang J, Blanck TJ and Recio-Pinto E: An approach to identify
microRNAs involved in neuropathic pain following a peripheral nerve
injury. Front Neurosci. 8:2662014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiangpan P, Qingsheng M, Zhiwen Y and Tao
Z: Emerging role of microRNA in neuropathic pain. Curr Drug Metab.
17:336–344. 2016. View Article : Google Scholar
|
|
37
|
Tan PH, Pao YY, Cheng JK, Hung KC and Liu
CC: MicroRNA-based therapy in pain medicine: Current progress and
future prospects. Acta Anaesthesiol Taiwan. 51:171–176. 2013.
View Article : Google Scholar
|
|
38
|
Kusuda R, Cadetti F, Ravanelli MI, Sousa
TA, Zanon S, De Lucca FL and Lucas G: Differential expression of
microRNAs in mouse pain models. Mol Pain. 7:172011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi G, Shi J, Liu K, Liu N, Wang Y, Fu Z,
Ding J, Jia L and Yuan W: Increased miR-195 aggravates neuropathic
pain by inhibiting autophagy following peripheral nerve injury.
Glia. 61:504–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Jiang Q, Wang M and Li D: MiR-19a
targets suppressor of cytokine signaling 1 to modulate the
progression of neuropathic pain. Int J Clin Exp Pathol.
8:10901–10907. 2015.PubMed/NCBI
|
|
41
|
Xia L, Zhang Y and Dong T: Inhibition of
microRNA-221 alleviates neuropathic pain through targeting
suppressor of cytokine signaling 1. J Mol Neurosci. 59:411–420.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen HP, Zhou W, Kang LM, Yan H, Zhang L,
Xu BH and Cai WH: Intrathecal miR-96 inhibits Nav1.3 expression and
alleviates neuropathic pain in rat following chronic construction
injury. Neurochem Res. 39:76–83. 2014. View Article : Google Scholar
|
|
43
|
Lin CR, Chen KH, Yang CH, Huang HW and
Sheen-Chen SM: Intrathecal miR-183 delivery suppresses mechanical
allodynia in mononeuropathic rats. Eur J Neurosci. 39:1682–1689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shao J, Cao J, Wang J, Ren X, Su S, Li M,
Li Z, Zhao Q and Zang W: MicroRNA-30b regulates expression of the
sodium channel Nav1.7 in nerve injury-induced neuropathic pain in
the rat. Mol Pain. Oct 19–2016.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lu Y, Cao DL, Jiang BC, Yang T and Gao YJ:
MicroRNA-146a-5p attenuates neuropathic pain via suppressing TRAF6
signaling in the spinal cord. Brain Behav Immun. 49:119–129. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang J, Zhang H and Zi T: Overexpression
of microRNA-141 relieves chronic constriction injury-induced
neuropathic pain via targeting high-mobility group box 1. Int J Mol
Med. 36:1433–1439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Leinders M, Üçeyler N, Pritchard RA,
Sommer C and Sorkin LS: Increased miR-132-3p expression is
associated with chronic neuropathic pain. Exp Neurol. 283:276–286.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heyn J, Luchting B, Hinske LC, Hübner M,
Azad SC and Kreth S: miR-124a and miR-155 enhance differentiation
of regulatory T cells in patients with neuropathic pain. J
Neuroinflammation. 13:2482016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ito N, Sakai A, Miyake N, Maruyama M,
Iwasaki H, Miyake K, Okada T, Sakamoto A and Suzuki H: miR-15b
mediates oxaliplatin-induced chronic neuropathic pain through BACE1
down-regulation. Br J Pharmacol. 174:386–395. 2017. View Article : Google Scholar
|
|
50
|
Neumann M and Naumann M: Beyond IkappaBs:
Alternative regulation of NF-kappaB activity. FASEB J.
21:2642–2654. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Maeda S and Omata M: Inflammation and
cancer: Role of nuclear factor-kappaB activation. Cancer Sci.
99:836–842. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sakaue G, Shimaoka M, Fukuoka T, Hiroi T,
Inoue T, Hashimoto N, Sakaguchi T, Sawa Y, Morishita R, Kiyono H,
et al: NF-kappa B decoy suppresses cytokine expression and thermal
hyperalgesia in a rat neuropathic pain model. Neuroreport.
12:2079–2084. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun T, Song WG, Fu ZJ, Liu ZH, Liu YM and
Yao SL: Alleviation of neuropathic pain by intrathecal injection of
antisense oligonucleotides to p65 subunit of NF-kappaB. Br J
Anaesth. 97:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Niederberger E and Geisslinger G: The
IKK-NF-kappaB pathway: A source for novel molecular drug targets in
pain therapy? FASEB J. 22:3432–3442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Schaefer JS, Attumi T, Opekun AR, Abraham
B, Hou J, Shelby H, Graham DY, Streckfus C and Klein JR: MicroRNA
signatures differentiate Crohn's disease from ulcerative colitis.
BMC Immunol. 16:52015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ralfkiaer U, Lindahl LM, Litman T,
Gjerdrum LM, Ahler CB, Gniadecki R, Marstrand T, Fredholm S,
Iversen L, Wasik MA, et al: MicroRNA expression in early mycosis
fungoides is distinctly different from atopic dermatitis and
advanced cutaneous T-cell lymphoma. Anticancer Res. 34:7207–7217.
2014.PubMed/NCBI
|
|
57
|
Pivarcsi A, Meisgen F, Xu N, Ståhle M and
Sonkoly E: Changes in the level of serum microRNAs in patients with
psoriasis after antitumour necrosis factor-α therapy. Br J
Dermatol. 169:563–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Boomiraj H, Mohankumar V, Lalitha P and
Devarajan B: Human corneal microRNA expression profile in fungal
keratitis. Invest Ophthalmol Vis Sci. 56:7939–7946. 2015.
View Article : Google Scholar
|
|
59
|
Perri R, Nares S, Zhang S, Barros SP and
Offenbacher S: MicroRNA modulation in obesity and periodontitis. J
Dent Res. 91:33–38. 2012. View Article : Google Scholar :
|
|
60
|
Yuan Z, Luo G, Li X, Chen J, Wu J and Peng
Y: PPARγ inhibits HMGB1 expression through upregulation of
miR-142-3p in vitro and in vivo. Cell Signal. 28:158–164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang Y, Ouyang M, Wang Q and Jian Z:
MicroRNA-142-3p inhibits hypoxia/reoxygenation induced apoptosis
and fibrosis of cardiomyocytes by targeting high mobility group box
1. Int J Mol Med. 38:1377–1386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xiao P and Liu WL: MiR-142-3p functions as
a potential tumor suppressor directly targeting HMGB1 in
non-small-cell lung carcinoma. Int J Clin Exp Pathol.
8:10800–10807. 2015.PubMed/NCBI
|
|
63
|
Feldman P, Due MR, Ripsch MS, Khanna R and
White FA: The persistent release of HMGB1 contributes to tactile
hyperalgesia in a rodent model of neuropathic pain. J
Neuroinflammation. 9:1802012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang FF, Morioka N, Harano S, Nakamura Y,
Liu K, Nishibori M, Hisaoka-Nakashima K and Nakata Y: Perineural
expression of high-mobility group box-1 contributes to long-lasting
mechanical hypersensitivity via matrix metalloproteinase-9
upregulation in mice with painful peripheral neuropathy. J
Neurochem. Nov 18–2015.Epub ahead of print. View Article : Google Scholar
|
|
65
|
Nakamura Y, Morioka N, Abe H, Zhang FF,
Hisaoka-Nakashima K, Liu K, Nishibori M and Nakata Y: Neuropathic
pain in rats with a partial sciatic nerve ligation is alleviated by
intravenous injection of monoclonal antibody to high mobility group
box-1. PLoS One. 8:e736402013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lin TB, Hsieh MC, Lai CY, Cheng JK, Wang
HH, Chau YP, Chen GD and Peng HY: Melatonin relieves neuropathic
allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4
shuttling-dependent epigenetic modification of hmgb1 transcription.
J Pineal Res. 60:263–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang YS, Li YY, Wang LH, Kang Y, Zhang J,
Liu ZQ, Wang K, Kaye AD and Chen L: Tanshinone IIA attenuates
chronic pancreatitis-induced pain in rats via downregulation of
HMGB1 and TRL4 expression in the spinal cord. Pain Physician.
18:E615–E628. 2015.PubMed/NCBI
|
|
68
|
Ma YQ, Chen YR, Leng YF and Wu ZW:
Tanshinone IIA downregulates HMGB1 and TLR4 expression in a spinal
nerve ligation model of neuropathic pain. Evid Based Complement
Alternat Med. 2014:6395632014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
He Z, Guo Q, Xiao M, He C and Zou W:
Intrathecal lentivirus- mediated transfer of interleukin-10
attenuates chronic constriction injury-induced neuropathic pain
through modulation of spinal high-mobility group box 1 in rats.
Pain Physician. 16:E615–E625. 2013.PubMed/NCBI
|
